UK Markets close in 6 hrs 54 mins
  • FTSE 100

    7,507.94
    +104.09 (+1.41%)
     
  • FTSE 250

    18,782.73
    +287.60 (+1.56%)
     
  • AIM

    803.78
    +6.56 (+0.82%)
     
  • GBP/EUR

    1.1404
    -0.0044 (-0.39%)
     
  • GBP/USD

    1.2245
    -0.0028 (-0.2241%)
     
  • BTC-GBP

    22,626.19
    -542.03 (-2.34%)
     
  • CMC Crypto 200

    600.74
    +1.07 (+0.18%)
     
  • S&P 500

    3,951.57
    +34.93 (+0.89%)
     
  • DOW

    32,244.58
    +382.60 (+1.20%)
     
  • CRUDE OIL

    68.12
    +0.48 (+0.71%)
     
  • GOLD FUTURES

    1,970.60
    -12.20 (-0.62%)
     
  • NIKKEI 225

    26,945.67
    -388.12 (-1.42%)
     
  • HANG SENG

    19,258.76
    +258.05 (+1.36%)
     
  • DAX

    15,149.63
    +216.25 (+1.45%)
     
  • CAC 40

    7,117.63
    +104.49 (+1.49%)
     

Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION

Hofseth Biocare ASA
Hofseth Biocare ASA

Bomi Framroze Holding AS, a close associate of primary insider and Chief Scientific Officer Dr. Bomi Framroze in Hofseth Biocare ASA ("HBC"), has on 27 February 2023 purchased 200,000 shares in HBC at a price of NOK 2.69 per share.

Please see the attached notification form for further information.

Jon Olav Ødegård, CEO of Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no

This information is subject to the disclosure requirements in the Market Abuse Regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading Act section 5-12.

Attachment